Broad Attendance at This Yr’s Congress Highlights Prothena’s Management in Advancing Subsequent Technology Therapies for Alzheimer’s and Parkinson’s Illness Oral presentation of PRX012, Prothenas next-generation amyloid-beta antibody for Alzheimer’s illness, demonstrates larger affinity binding to amyloid-beta protofibrils and better clearance of amyloid-beta-pyroglutamate plaques in comparison with different accredited and experimental molecules Prothena Participates in Alzheimer’s AD/PD Discussion board Discussions and Hosts an Business-Sponsored Symposium Roche Accomplice Symposium Posters and Shows on the Section 2 PASADENA Examine of Prasinezumab for Parkinson’s Illness DUBLIN, March 14, 2023–(BUSINESS WIRE)–Prothena Company plc (NASDAQ:PRTA), an late-stage medical biotechnology firm with a strong pipeline of investigational therapeutics based mostly on experience in protein dysregulation, at the…